Charles River Laboratories International, Inc.
CRL
$138.79
-$2.57-1.82%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.16% | -1.92% | -3.67% | -2.41% | 0.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.16% | -1.92% | -3.67% | -2.41% | 0.49% |
| Cost of Revenue | 0.24% | 1.19% | -1.40% | 0.16% | 1.79% |
| Gross Profit | -6.42% | -7.31% | -7.54% | -6.73% | -1.72% |
| SG&A Expenses | -2.76% | -2.18% | -3.73% | -6.29% | 8.10% |
| Depreciation & Amortization | 0.42% | 0.75% | -5.46% | -5.04% | -5.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.39% | 0.46% | -2.05% | -1.44% | 2.74% |
| Operating Income | -12.42% | -15.04% | -12.26% | -7.59% | -10.79% |
| Income Before Tax | -94.52% | -83.98% | -16.01% | -13.94% | -14.60% |
| Income Tax Expenses | -45.71% | -32.79% | -33.84% | -31.31% | -30.66% |
| Earnings from Continuing Operations | -105.17% | -94.74% | -10.93% | -9.06% | -10.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 83.65% | -51.74% | -76.52% | -61.70% | -141.47% |
| Net Income | -105.76% | -96.51% | -11.96% | -9.95% | -11.59% |
| EBIT | -12.42% | -15.04% | -12.26% | -7.59% | -10.79% |
| EBITDA | -4.94% | -6.04% | -5.41% | -2.69% | -5.74% |
| EPS Basic | -107.41% | -98.13% | -13.56% | -11.44% | -12.25% |
| Normalized Basic EPS | -16.85% | -20.21% | -8.37% | -6.61% | -11.38% |
| EPS Diluted | -107.62% | -98.35% | -13.46% | -11.38% | -12.03% |
| Normalized Diluted EPS | -16.67% | -20.15% | -8.29% | -6.55% | -11.21% |
| Average Basic Shares Outstanding | -0.24% | 0.30% | 0.58% | 0.73% | 0.76% |
| Average Diluted Shares Outstanding | -0.54% | 0.14% | 0.49% | 0.66% | 0.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |